Granules India

Granules India promoter Dr Krishna Prasad Chigurupati sold 1.72 crore shares on September 11 through a block deal and open-market transactions, with the proceeds intended to fund the second tranche of the company’s ongoing preferential issue. The aggregate promoter and promoter-group holding fell from 38.02% to 31.08% of paid-up equity, while Chigurupati’s individual stake declined from 31.00% to 24.06%; the diluted promoter-group holding stood at 37.39%. Capital Group, Kotak Mahindra Life Insurance Company, ChrysCapital and Allspring were among the institutional participants. In November 2025, Granules approved 25 million warrants at ₹585 a share, and ₹366 crore of warrant proceeds were received in the first quarter of FY27. Revenue in FY26 was ₹5,366 crore and profit after tax was ₹595 crore.

Powered by Tijori

Sept 11 (Reuters) - Granules India Limited GRAN.NS:

• PROMOTER KRISHNA PRASAD CHIGURUPATI SELLS 17.2 MILLION SHARES OF CO VIA BLOCK DEAL

• TRANSACTION UNDERTAKEN TO FUND SECOND TRANCHE OF CO'S ONGOING PREFERENTIAL ISSUE

• SHAREHOLDING OF PROMOTER GROUP IN COMPANY HAS CHANGED FROM 38.02% TO 31.08%

Further company coverage: GRAN.NS

(([email protected];))

July 21 (Reuters) - Drugmaker Granules India GRAN.NS reported a nearly 60% rise in first-quarter profit on Tuesday as margins improved in its complex generics business.

Consolidated net profit for the quarter ended June 30 rose to 1.8 billion rupees ($18.71 million), compared to 1.13 billion rupees a year earlier, when it had booked a one-time charge.

Here are some key details:

• Total revenue from operations climbed 22% to 14.77 billion rupees on higher sales of finished medicines.

• Profit was helped by margin expansion due to a better mix of products sold, the company said, offsetting a 17% increase in expenses.

• The drugmaker incurred a one-time charge of 259.1 million rupees in the year-ago period tied to its acquisition of Senn Chemicals and settlement of certain legal cases.

• Granules accounts for about 30% of the global market for paracetamol and operates 10 manufacturing plants worldwide - seven in India, two in the U.S. and one in Europe.

• Analysts at Choice Equity Broking expected revenue to grow on the back of robust demand for its peptide and contract manufacturing drugs, and flagged the company's oncology launch pipeline and an U.S. FDA approvals as key focus areas for investors.

• Shares of the company rose as much as 3.2% after results.

($1 = 96.2250 Indian rupees)

(Reporting by Mridula Kumar in Bengaluru; Editing by Harikrishnan Nair)

(([email protected]))

Granules India secured sole first-to-file status for its Abbreviated New Drug Application for Sodium Oxybate Extended-Release for Oral Suspension, the generic version of LUMRYZ. The designation was announced in a press release on July 6, 2026, and marks the company's second sole first-to-file ANDA success, following an earlier one for Amphetamine Extended-Release Tablets. LUMRYZ, registered to Alkermes plc, is indicated for cataplexy or excessive daytime sleepiness in narcolepsy patients. The sole first-to-file status could grant Granules 180 days of generic exclusivity, enhancing its competitive position in the U.S. market. Chairman and Managing Director Dr. Krishna Prasad Chigurupati described the milestone as an important step in the company's complex generics journey.

Powered by Tijori

July 6 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - SECURES FIRST-TO-FILE ANDA STATUS FOR GENERIC LUMRYZ

Source text: ID:nBSE464Rbn

Further company coverage: GRAN.NS

(([email protected];))

June 3 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - RECEIVES US FDA EIR WITH VOLUNTARY ACTION INDICATED FOR CHANTILLY FACILITY

• GRANULES - FOUR FORM 483 OBSERVATIONS ISSUED DURING MARCH 30-APRIL 3, 2026 INSPECTION

Source text: ID:nNSE2qnM0s

Further company coverage: GRAN.NS

(([email protected];))

** Shares of India's Granules GRAN.NS jump 1.30% to 713.70 rupees

** Drugmaker's Q4 profit jumps 32.6% y/y to 2.02 billion rupees ($21.30 million), on strong demand for key products across major markets

** Total revenue from operations rises 21.7% y/y

** Europe's revenue share rose to 17% in Q4 FY26 from 8% in Q4 FY25

** Emkay said regulatory clearance of the Gagillapur facility in FY27 could boost formulation sales; introduces FY29 estimates and expects ~26% PAT CAGR over FY26–FY29

** GRAN rated "buy" on average by seven analysts, median PT: 685 rupees - data compiled by LSEG

** YTD, stock up ~18.6%

($1 = 94.8400 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

April 29 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - RECOMMENDS FINAL DIVIDEND OF 1.75 RUPEE PER SHARE FOR FY2025-26

• GRANULES INDIA Q4 CONSOL PROFIT 2.02 BILLION RUPEES

• GRANULES INDIA Q4 CONSOL TOTAL REVENUE FROM OPERATIONS 14.71 BILLION RUPEES

Source text: ID:nBSEbW3nDy

Further company coverage: GRAN.NS

(([email protected];;))

March 31 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - RECEIVES VAI CLASSIFICATION FOLLOWING US FDA INSPECTION

• GRANULES - INSPECTION IS NOW CLOSED, NO REGULATORY ACTION HAS BEEN RECOMMENDED

Source text: ID:nBSE1HyjKN

Further company coverage: GRAN.NS

(([email protected];;))

March 5 (Reuters) - Granules India Ltd GRAN.NS:

• PACKAGING FACILITY IN US GETS FDA EIR WITH NO ACTION INDICATED STATUS

Source text: ID:nnAZN4SJL8U

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS rise 2.8% to 580.80 rupees

** Paracetamol maker's Q3 profit up 28% driven by strong demand in its key European and North American markets

** Co's Q3 consol profit up to 1.5 billion rupees vs 1.18 billion rupees y/y

** North America, which generates about two-thirds of the firm's revenue, logged a 14% jump in sales; Europe sales, which contribute 19% to topline, more than doubled

** Current production coming back on stream, ramp-up in new launches in the U.S. and other geographies, coupled with improved volumes- Dolat Capital

** GRAN down nearly 3% so far in January

(Reporting by Urvi Dugar in Bengaluru)

(([email protected];))

Jan 23 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES DEC-QUARTER CONSOL PROFIT 1.50 BILLION RUPEES

• GRANULES DEC-QUARTER CONSOL SALE OF PRODUCTS 13.78 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];))

Jan 8 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT RECEIVES FDA TENTATIVE APPROVAL FOR GENERIC AMPHETAMINE WITH 180-DAY EXCLUSIVITY

Source text: ID:nNSE826LQ6

Further company coverage: GRAN.NS

(([email protected];))

Dec 12 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT RECEIVES EIR FROM FDA

Source text: ID:nNSE7p3B0h

Further company coverage: GRAN.NS

(([email protected];))

Nov 13 (Reuters) - Granules India Ltd GRAN.NS:

• Q2 CONSOL PROFIT 1.31 BILLION RUPEES

• Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 12.97 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];;))

June 20 (Reuters) - Granules India Ltd GRAN.NS:

• BONTHAPALLY FACILITY COMPLETES US FDA INSPECTION

• FACILITY COMPLETED FDA INSPECTION WITH ONE 483 OBSERVATION

Source text: ID:nNSEbcFQWR

Further company coverage: GRAN.NS

(([email protected];;))

** Indian pharma stocks .NIPHARM gain 1.4%

** Donald Trump signs executive order directing drugmakers to lower prices of their medicines to align with what other countries pay

** But, the order was not as bad as feared, investors, analysts and drug pricing experts said

** Pharma stocks declined in early trade on Monday after Trump's announcement

** HDFC Securities says generic drugmakers unlikely to have any impact

** Adds Sun Pharma SUN.NS to see some impact of price ceiling on specialty products like psoriasis drug Ilumya and anti-baldness drug Leqselvi

** Glenmark Pharma GLEN.NS, Divi's Laboratories DIVI.NS climb 3% each; SUN rises 0.6%

** Lupin LUPN.NS, Granules India GRAN.NS and Biocon BION.NS gain 2.6%, 3.8% and 1.7% respectively

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

April 10 (Reuters) - Granules India Ltd GRAN.NS:

• CLOSING OF ACQUISITION OF SENN CHEMICALS

Further company coverage: GRAN.NS

(([email protected];))

March 25 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - BOARD APPROVES INTERNAL RESTRUCTURING PLAN FOR US SUBSIDIARIES

• GRANULES INDIA LTD - NO CHANGE IN ULTIMATE OWNERSHIP OR BUSINESS NATURE IN US

Source text: ID:nBSE3nGBP8

Further company coverage: GRAN.NS

(([email protected];))

March 18 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT GRANULES EUROPE HAS BEEN VOLUNTARILY DISSOLVED

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of pharma co Granules India GRAN.NS fall 2.4% to 460 rupees

** Stock among top losers on Nifty Pharma index .NIPHARM

** The US FDA issued a warning letter to co post inspection

** Reports says bird droppings and feathers were found on air purification units, ducts, tank etc

** Flagged issues including lack of written procedures for equipment cleaning, residues and microbial contamination in ducts, risking cross-contamination

** More than 2.2 mln shares change hands, 1.6x its 30-day avg

** Stock down ~21% YTD vs a ~15% drop in NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Feb 28 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - GOT ORDER FOR CLOSURE OF PROCEEDINGS OF INVESTIGATION AFTER PAYMENT OF DUES

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS climb 2.2% to 520 rupees

** Pharma co says it signed agreement to acquire Switzerland-based Senn Chemicals AG

** Co adds, acquisition is expected to close in the

first half of 2025

** Financial details of the deal was not disclosed

** Stock set to log gains after falling for two straight sessions

** Stock down ~14% YTD vs ~13% fall in broader Nifty Pharma index .NIPHARM

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 21 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - TO ACQUIRE 100% EQUITY STAKE IN SENN CHEMICALS AG

• GRANULES: DEAL FOR 1.93 BILLION RUPEES

Source text: ID:nNSE1PXl9y

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of Granules India GRAN.NS rise 3.6% to 565.2 rupees

** Pharma co said on Wednesday its Unit V facility received European Union good manufacturing practice certificate for active pharmaceutical ingredients (APIs) and finished dosages

** Certification implies co has been assessed and deemed to meet EU safety, health and environmental protection requirements

** Audit of the facility was done in Nov 2024, co says

** Stock gained 46% in 2024

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Jan 29 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT V RECEIVES EU GMP CERTIFICATE

• EU AUTHORITY CONDUCTED AUDIT OF GRANULES INDIA UNIT V IN NOVEMBER 2024

Source text: ID:nBSE5nkvmM

Further company coverage: GRAN.NS

(([email protected];;))

Jan 24 (Reuters) - Granules India Ltd GRAN.NS:

• Q3 CONSOL PROFIT 1.18 BILLION RUPEES

• Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 11.38 BILLION RUPEES

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of Granules India GRAN.NS turn positive, up 0.7% at 588.40 rupees

** Pharma co's unit gets US FDA's approval for Lisdexamfetamine Dimesylate chewable tablets, a generic for Vyvanse chewable tablets

** Lisdexamfetamine dimesylate tablets are used to treat attention deficit hyperactivity disorder and binge eating disorder

** Stock was down ~0.5% before disclosure of US FDA approval for unit's drug

** GRAN up ~45% YTD vs gains of 27% in 2023

(Reporting by Vijay Malkar)

(([email protected];))

Dec 4 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - UPDATE ON US FDA INSPECTION AT GAGILLAPUR FACILITY

• GRANULES INDIA LTD - OAI CLASSIFICATION DOES NOT IMPACT ONGOING MANUFACTURING OR DISTRIBUTION

• GRANULES INDIA LTD - OAI STATUS MAY IMPACT REVIEW OF PENDING SUBMISSIONS FOR NEW PRODUCTS

Source text: ID:nnAPN2FLDZF

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharmaceuticals maker Granules India GRAN.NS close down 10.3%

** This is only the second session this year that the stock has declined by 10% or more

** Stock top loser on the Nifty Pharma index .NIPHARM, which slips about 0.1%

** US FDA classifies inspection co's Gagillapur facility as 'official action indicated' (OAI); the classification means regulatory or administrative actions are recommended

** Co says it has responded to all observations issued by the US FDA and voluntarily undertaken evaluation of facility, in consultation with external subject matter experts

** Trading vols at 18.4 mln, highest since mid-September

** GRAN stock has risen around 32% YTD, NIPHARM also up about 33%

(Reporting by Vijay Malkar)

(([email protected];))